Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 21 of the 26 references it cites were found in a registry or an index; 4 of the 8 sources its claims cite were checked for support.

Global impact of the first year of COVID-19 vaccination: a mathematical modelling study

Open access

Abstract

BACKGROUND: The first COVID-19 vaccine outside a clinical trial setting was administered on Dec 8, 2020. To ensure global vaccine equity, vaccine targets were set by the COVID-19 Vaccines Global Access (COVAX) Facility and WHO. However, due to vaccine shortfalls, these targets were not achieved by the end of 2021. We aimed to quantify the global impact of the first year of COVID-19 vaccination programmes. METHODS: A mathematical model of COVID-19 transmission and vaccination was separately fit to reported COVID-19 mortality and all-cause excess mortality in 185 countries and territories. The impact of COVID-19 vaccination programmes was determined by estimating the additional lives lost if no vaccines had been distributed. We also estimated the additional deaths that would have been averted had the vaccination coverage targets of 20% set by COVAX and 40% set by WHO been achieved by the end of 2021. FINDINGS: Based on official reported COVID-19 deaths, we estimated that vaccinations prevented 14·4 million (95% credible interval [Crl] 13·7-15·9) deaths from COVID-19 in 185 countries and territories between Dec 8, 2020, and Dec 8, 2021. This estimate rose to 19·8 million (95% Crl 19·1-20·4) deaths from COVID-19 averted when we used excess deaths as an estimate of the true extent of the pandemic, representing a global reduction of 63% in total deaths (19·8 million of 31·4 million) during the first year of COVID-19 vaccination. In COVAX Advance Market Commitment countries, we estimated that 41% of excess mortality (7·4 million [95% Crl 6·8-7·7] of 17·9 million deaths) was averted. In low-income countries, we estimated that an additional 45% (95% CrI 42-49) of deaths could have been averted had the 20% vaccination coverage target set by COVAX been met by each country, and that an additional 111% (105-118) of deaths could have been averted had the 40% target set by WHO been met by each country by the end of 2021. INTERPRETATION: COVID-19 vaccination has substantially altered the course of the pandemic, saving tens of millions of lives globally. However, inadequate access to vaccines in low-income countries has limited the impact in these settings, reinforcing the need for global vaccine equity and coverage. FUNDING: Schmidt Science Fellowship in partnership with the Rhodes Trust; WHO; UK Medical Research Council; Gavi, the Vaccine Alliance; Bill & Melinda Gates Foundation; National Institute for Health Research; and Community Jameel.

Overview

CoChat Summary

## TL;DR

This mathematical modelling study estimated that COVID-19 vaccination averted 14.4 million deaths based on reported deaths, or 19.8 million deaths when excess mortality was used, across 185 countries and territories during Dec 8, 2020–Dec 8, 2021. The paper argues that vaccine inequity limited impact in low-income settings and that reaching COVAX/WHO coverage targets could have saved substantially more lives.

## Key findings

  • Using officially reported COVID-19 deaths, vaccination prevented 14.4 million deaths (95% CrI 13.7–15.9) in 185 countries and territories over the first year of vaccination.
  • Using excess mortality, vaccination averted 19.8 million deaths (95% CrI 19.1–20.4), corresponding to a 63% reduction in total deaths (19.8 million of 31.4 million) during that year.
  • In COVAX AMC countries, vaccinations averted 7.4 million deaths (95% CrI 6.8–7.7), representing 41% of estimated excess mortality (7.4 million of 17.9 million).
  • If the WHO 40% target had been met in every country by the end of 2021, an additional 599,300 deaths (95% CrI 577,700–622,400) could have been averted; in low-income countries, meeting the COVAX 20% target could have averted an additional 45% of deaths, and the WHO 40% target an additional 111% of deaths.

## Methods

  • The authors fit a previously published age-structured SEIRS transmission model with vaccination to reported COVID-19 mortality and to all-cause excess mortality in 185 countries and territories (excluding China), using country-level demography, mixing patterns, health-care capacity, and vaccination rollout data.
  • Vaccination effects were modelled as protection against infection, severe disease, and onward transmission; the model also explicitly represented the delta variant and vaccine efficacy by country based on likely vaccine types used.
  • They estimated deaths averted by comparing the fitted observed scenario against counterfactual scenarios with no vaccines, and with vaccines distributed to meet COVAX 20% and WHO 40% coverage targets by Dec 8, 2021, using Bayesian fitting with Metropolis-Hastings MCMC and 100 draws for uncertainty.

## Limitations

  • The paper states that impact estimates were limited by uncertainty in excess mortality, gaps in genomic surveillance, and lack of detailed vaccination data for many countries; key inputs had to rely on working assumptions about vaccine type, rollout, and variant spread.
  • The authors explicitly note a limitation of the COVAX/WHO target analysis: the targets were meant for the end of 2021, while the modelling endpoint was Dec 8, 2021, so some countries may have been closer to target by year-end than the model captured.
  • Evident from the text: the counterfactual did not adjust for how governments or populations might have responded without vaccines, nor for possible changes in mobility, non-pharmaceutical interventions, or viral evolution, so the estimated deaths averted are model-dependent.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1016/s1473-3099(22)00320-6

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Global COVID-19 deaths averted due to vaccination based on excess mortality (A) Median number of daily COVID-19 deaths based on excess mortality estimates (grey vertical bars) in the first year of vaccination. The baseline estimate of daily COVID-19 deaths from the model fit to excess mortality is plotted with the solid black line and the counterfactual scenario without vaccines is plotted with a red line. The gap between the red and black line indicates the deaths averted due to vaccination, with the proportion of total deaths averted by direct protection conferred by vaccination shown in blue and indirect protection shown in green. (B) Median number of daily deaths averted per day as per 2022 World Bank income group.
Figure 1 Global COVID-19 deaths averted due to vaccination based on excess mortality (A) Median number of daily COVID-19 deaths based on excess mortality estimates (grey vertical bars) in the first year of vaccination. The baseline estimate of daily COVID-19 deaths from the model fit to excess mortality is plotted with the solid black line and the counterfactual scenario without vaccines is plotted with a red line. The gap between the red and black line indicates the deaths averted due to vaccination, with the proportion of total deaths averted by direct protection conferred by vaccination shown in blue and indirect protection shown in green. (B) Median number of daily deaths averted per day as per 2022 World Bank income group.CC BY · PubMed Central
Figure 2 Median deaths averted by vaccinations per 10 000 people by country in the first year of COVID-19 vaccination Estimates of deaths averted were based on model fits to excess mortality and were binned within seven equal quantiles starting at 0 deaths averted. Deaths averted listed as not applicable for China because of its exclusion from our analysis, due to its unique position as the origin of the detected epidemic and large influence on estimates of deaths averted stemming from its population size.
Figure 2 Median deaths averted by vaccinations per 10 000 people by country in the first year of COVID-19 vaccination Estimates of deaths averted were based on model fits to excess mortality and were binned within seven equal quantiles starting at 0 deaths averted. Deaths averted listed as not applicable for China because of its exclusion from our analysis, due to its unique position as the origin of the detected epidemic and large influence on estimates of deaths averted stemming from its population size.CC BY · PubMed Central
Figure 3 Median deaths averted by vaccinations per 10 000 against vaccinations per 10 000 for each country All measures are on the log-scale. Spearman's rank correlation coefficient (Spearman's ρ) is also given for each income group with a p value based on the Z score against a null hypothesis of no correlation. Countries that did not deliver any vaccinations or had no deaths averted are not included.
Figure 3 Median deaths averted by vaccinations per 10 000 against vaccinations per 10 000 for each country All measures are on the log-scale. Spearman's rank correlation coefficient (Spearman's ρ) is also given for each income group with a p value based on the Z score against a null hypothesis of no correlation. Countries that did not deliver any vaccinations or had no deaths averted are not included.CC BY · PubMed Central

Verification

Claims the paper makes

2 Valid · 2 Not valid · 4 Not checked · 48 Own results and interpretations

32 more claims

Create a free account to see all 56 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 14
  • Probably not a substantial claim. 6

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 26 references

Research works printed but not linked: 2

  1. Wee, 2021, They had the vaccines and a plan to reopen. Instead they got cold feet, The New York Times
  2. 2021, The pandemic's true death toll, The Economist

Cited by

See all 1,777

Metadata

Authors
Watson, O. J., Barnsley, G., Toor, J., Hogan, A. B., Winskill, P., & Ghani, A. C.
Affiliations
Imperial College London (GB)
Corresponding author
Watson, Oliver J
Venue
The Lancet Infectious Diseases
Publisher
Elsevier BV
Published
2022-09
Volume
22
Issue
9
Pages
1293-1302
ISSN
1473-3099 (ISSN-L)
OpenAlex
W4283395367
Cited by
1,769
References
26
Citations by year
2026: 165 · 2025: 341 · 2024: 533 · 2023: 578 · 2022: 150
FWCI
237.54
Type
journal article
Language
en
Update notices
erratum (2023-10-01)
Open access
Licence
Locations
  • The Lancet Infectious Diseases (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
  • Spiral (Imperial College London) (submittedVersion, other-oa)
Funders
  • Bill and Melinda Gates Foundation
  • GAVI Alliance
  • National Institute for Health and Care Research
  • Imperial College London
  • Medical Research Council (MR/R015600/1, MC_PC_19012)
Topics
  • Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Social Sciences › Health › Vaccine Coverage and Hesitancy
Keywords
COVID-19 vaccination, vaccine impact, COVID-19 mortality, excess mortality, mortality averted, COVAX, vaccine equity, low-income countries, mathematical transmission model, global health equity, SARS-CoV-2, advance market commitments
MeSH terms
COVID-19, COVID-19 Vaccines, Humans, Models, Theoretical, Vaccination, Vaccines, Global Health

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. https://app.cochat.ai/papers/10.1016/s1473-3099(22)00320-6
The paper
Watson, O. J., Barnsley, G., Toor, J., Hogan, A. B., Winskill, P., & Ghani, A. C. (2022). Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(22)00320-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.